Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration

scientific article published in September 2003

Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/00002030-200309050-00008
P698PubMed publication ID12960822

P50authorHans-Jürgen StellbrinkQ47158312
Jan van LunzenQ47159113
P2093author name stringHans-Jürgen Stellbrink
Kurt Hertogs
Christian Eggers
Hans-Jörg Stürenburg
P433issue13
P407language of work or nameEnglishQ1860
P921main subjectHIV encephalopathyQ18967433
viral drug resistanceQ71228770
P304page(s)1897-1906
P577publication date2003-09-01
P1433published inAIDSQ4651863
P1476titleDelayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration
P478volume17

Reverse relations

cites work (P2860)
Q34387874Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study
Q37066982Antiretroviral therapy and central nervous system HIV type 1 infection
Q34298792Antiretroviral therapy in macrophages: implication for HIV eradication
Q36344916Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection
Q36798111Better Antiretroviral Central Nervous System Penetration is Not Associated with Reduced Chronic Pain in People Living with Human Immunodeficiency Virus
Q31155550CNS infections in immunocompromised patients
Q38060571CSF penetration by antiretroviral drugs
Q34080236Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research
Q42233102Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients
Q24814874Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment
Q82029827Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex
Q58598991Changes in resting-state functional brain activity are associated with waning cognitive functions in HIV-infected children
Q37715012Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option
Q44367684Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders
Q28475360Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia
Q33843510Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells
Q37787605Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system?
Q34950897Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course
Q33786313Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals
Q37015519Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers
Q37176655Effects of antiretroviral therapy on cognitive impairment
Q42264249Genetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy.
Q41712400HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management
Q36552753HIV pharmacology: barriers to the eradication of HIV from the CNS.
Q39548875HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy
Q30234305HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.
Q46812278Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy
Q45549650Immunodetection of a hepatitis C virus (HCV) antigen and Thl/Th2 cytokines in cerebrospinal fluid of meningitis patients
Q33911855Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia
Q37395149Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.
Q82029838Neuropharmacology of HIV/AIDS
Q36003825Neuroprotective strategies for HIV-1 associated dementia.
Q38247035Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system
Q37371300Second assessment of NeuroAIDS in Africa
Q36957941Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals
Q37362071Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?
Q36906028The meningeal lymphatic system: a route for HIV brain migration?
Q42203691Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics
Q48687135Using gene delivery to protect HIV-susceptible CNS cells: inhibiting HIV replication in microglia.
Q37390163Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

Search more.